The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydrolase (e.g., ASPH), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders.

The present invention relates to compounds which modulate (e.g., inhibit) the activity of beta-hydrolase (e.g., ASPH), including novel 2-aryl-5-amino-3(2H)-furanone and 2-heteroaryl-5-amino-3(2H)-furanone compounds, pharmaceutical compositions thereof, methods for their synthesis, and methods of using these compounds to modulate the activity of ASPH in an a cell-free sample, a cell-based assay, and in a subject. Other aspects of the invention relate to use of the compounds disclosed herein to ameliorate or treat cell proliferation disorders.

An ionic liquid additive for lithium-ion battery

An ionic liquid for adding to an electrolyte of a lithium-ion battery, the ionic liquid comprises a compound with a dual core structure having the general formula (I):

##STR00001## wherein each of cationic group X.sub.1 and X.sub.2 are heterocyclic aromatic and amine.

The invention provides capsaicinoid prodrug compounds, pharmaceutical compositions, and their use in the treatment of medical conditions, such as pain, and in agonizing TRPV1 activity.

Inhibitors of ALCAT1 are described having the general formula: (I). These compounds offer a treatment for aging and age-related diseases.

##STR00001##

A compound that is fluidized by light irradiation and reversibly non-fluidized and is represented by the following general formula (1):

##STR00001##

In the general formula (1), Ar.sub.1 and Ar.sub.2 each independently represent an aromatic hydrocarbon group optionally having a substituent or an aromatic heterocyclic group optionally having a substituent, and Y, Z.sub.1, and Z.sub.2 each independently represent a hydrogen atom or a lower alkyl group.

A compound that is fluidized by light irradiation and reversibly non-fluidized and is represented by the following general formula (1):

##STR00001##

In the general formula (1), Ar.sub.1 and Ar.sub.2 each independently represent an aromatic hydrocarbon group optionally having a substituent or an aromatic heterocyclic group optionally having a substituent, and Y, Z.sub.1, and Z.sub.2 each independently represent a hydrogen atom or a lower alkyl group.

Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).